CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulation glycolysis[1].

CBR-470-2 (1-10 μM; 24 h) increases transcript levels of the NRF2-responsive genes NQO1 and HMOX1 in epidermal keratinocytes and dermal fibroblasts[1].

CBR-470-2 (50 mg/kg; p.o. twice daily for 10 d) induces activation of NRF2 signaling in vivo[1]. Animal Model: Balb/C mice (5-week old) are exposed to UVB[1]

2416095-00-4

C12H13Cl2NO6S2

402.27

CBR-470-2

DMSO:200 mg/mL (497.18 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years